Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it will host a live webcast in conjunction with its Research and Development (R&D) Day on Wednesday, December 10, 2014, from 8:00 a.m. to 3:30 p.m. EST at the Alexandria Center in New York City.
...
http://www.shire.com/shireplc/en/media/shirenews?id=1045
.-
We need great news ...
I prefer to say: Maza bless us !!!
Only CEO Maza can decide whether to make the Reverse Split, before or after big news ...
It will make the difference between the wealth or the loss of great part of the capital invested by shareholders!
.-
I believe that many shareholders see a link between Dr. Frost, Dr. Chain, CEO Maza (and more), also a link between TEVA, COCP, CereSpir, ILNS, (and more) ...
Definitely something very good is cooking in the pot ...
Problem is the greed of men, if Dr. Frost, Dr. Chain, CEO Maza, will make us eat at their table, all old shareholders get rich. Otherwise, shareholders will be forced to eat what is left on the plate!
.-
BZNE ( ticker, to who did not understand ) no longer exists ...
.-
Changed CEO in 2014 and BZNE no longer exists ...
http://cocrystalpharma.com/news/news.php?date=140103
http://cocrystalpharma.com/news/news.php?date=140415
http://cocrystalpharma.com/COCP_inform.pdf
.-
Thanks, I cannot believe that Oing made great mess!
I had great confidence on him ... I'm disappointed now!
... and about Reverse Split ... what happened?
.-
Please, can anyone summarize the Oing's decision?
- I did not see no more postponement ...
- I did not see no verdict by Oing ...
Is it normal procedure ... what happened ?
.
What does it mean "REVOKE" for a shareholder who owns shares MTCH in portfolio?
a) Loss all invested capital ...
b) Hope recover something ...
Thanks !
.
Acquiring firm:
CereSpir ?, ex Viropharma or ex Shire ?, AbbVie ?, unknown ... ?
.,
... The acquiring firm holds the company for a few years to avoid the watchful eyes of shareholders. ...
The Repackaging Plan
The repackaging plan usually involves a private equity company using leveraged loans from the outside to take a currently public company private by buying all of its outstanding stock. The buying firm's goal is to repackage the company and return it to the marketplace in an initial public offering (IPO).
The acquiring firm holds the company for a few years to avoid the watchful eyes of shareholders. This allows the acquiring company to repackage the company behind closed doors, making adjustments here and there and dressing it up. When this is done on a large scale, private firms can buy many companies at once in an attempt to diversify their risk among various industries. Once the acquired company is dressed up, it is offered back to the market as an IPO with some fanfare.
Those who stand to benefit from a deal like this are the original shareholders (if the offer price is greater than the market price), the company's employees (if the deal saves the company from failure) and the private equity firm that generates fees from the day the buyout process starts and holds a portion of the stock until it goes public again. Unfortunately, if no major changes are made to the company, it's a zero-sum game and the new shareholders get the same financials the old company had.
.,
I would like to buy more shares in order to obtain an average value down ...
Unfortunately there are too many variables and no certainty ...
However, I believe that by several months already have been a merger between Intellect and Cerespir, before AbbVie bought Shire ...
Probably, Intellect / CereSpir received a proposal from AbbVie for complete sale of two companies merged ...
This complicates further the predictions and expectations for the shareholders of Intellect!
.,
Did you and Maza talk about Outstanding Shares?
Thanks
.,
The PROBLEM IS DOUBLE because after the Reverse Split 250 to 1, the number of Outstanding Shares will switch from current 350 million to 350: 250 = 1.4 million shares ...
Surely, it is too small as number, so at least they will issue 48.6 million new shares ...
I want to hope that Preferred Shares will be converted into Outstanding Shares, otherwise who is still with shares in the hand will receive another stab to the heart ... and new theft to wallet !
.,
Mr. Impacto, perhaps you only know what you write!
I'm sorry, but none of us has the key to decrypt your words ...
In next posts you try to explain what you want to say!
Thanks by all shareholders.
.,
Who sold in the past days to $ 0007 / ... 6 / ... 5 buys a greater number of shares, or buys the same number of shares plus $ cash!
.,
I believe that is a descent generated by shareholders who abandon the ship on the left side and the next day they go up on the right side ...
Several shareholders sold shares in the past days for $ 0.007 and bought back today to $ 0.0035 ...
They have doubled the number of shares held by them in few days ...
Who has strong heart can repeat this operation until bottoming out at $ 0.001 ...
I have been afraid to do these movements because if we get a sudden good news, it will be impossible to get back on board ship ...
.,
What do you think about?
Can CEO Maza shut down Reverse Split if he receive a proposal from Big Pharma "ROCHE" for buyout or merger?
I hope so ... !
.,
BUYING LEVELS:
- Traders buy before the news come
- Investors buy after the news come
- Big players buy after the stock over $ 1
- Hedge Funds buy after the stock over $ 5
.,
HYPOTHETICAL SCENARIO IN THE COMING MONTHS:
1)
CereSpir, many months in silence, could soon communicate the Fast Track approval by the FDA of CSP1103 (ex CHF 5074). At the same time, ILNS could communicate with the merger CereSpir and the return of Dr. Chain as CEO. In this case, the PPS could rise above $ 10 ... (Unfortunately, only a portion of the shareholders will be able to recover all the capital invested in ILNS).
2)
AbbVie may already be in talks with ILNS to buy the whole company with the entire portfolio ... In this case, to shareholders will be asked to choose between a number of
shares AbbVie, or $ (?) for each share owned ILNS .
3)
Ffizer buy ILNS after the date of October 2014, after the final results of the Clinical Trial of
Ponezumab. PPS $ ( ? )
4)
In reference to Roche Pharma plans to focus on small acquisitions and partnerships, ( see website: What we are looking for - http://www.roche.com ), I sent an email on July to report ILNS and I received a response of their interest and a quick study / research on Intellect. ... PPS $ ( ? ).
.,
Can a judge does not allow the publication of a judgment?
For what reasons?
.,
If we read well between the words, and if we consider the enthusiasm of Mr. Maza to write a detailed letter to shareholders, we can believe that we already had in place an agreement with Shire Pharma for a merger.
Probably, the merger agreement is taking place at this time with AbbVie Pharma ...
However, something very good is brewing because Mr. Maza has left out important topics for us ... probably these updates have become small details with little meaning ...
.,
Good idea!
You can mark my questions about:
- EVLI ...
- Outstanding Shares ...
Thanks !
.,
Understanding Leveraged Buyouts:
- Leveraged Buyouts ...
- Common Buyout Scenarios and Positive and Negative Effects of LBOs ...
- The Repackaging Plan ...
- The Split-Up ...
- The Portfolio Plan ...
- The Savior Plan ...
- The Bottom Line ...
http://www.investopedia.com/articles/financial-theory/08/leveraged-buyouts.asp
.,
Private equity firms mull merger of older GSK, Sanofi brands: FT
Sun Aug 3, 2014
(Reuters) - Private equity firms are mulling over a $10 billion plan to buy and merge older drug brands of Britain's GlaxoSmithKline (GSK.L) and France's Sanofi (SASY.PA), the Financial Times reported on Sunday, citing sources. ...
http://www.reuters.com/article/2014/08/03/us-gsk-sanofi-privateequity-idUSKBN0G30PJ20140803
----------------------------------------------------------------
GSK Option and License Agreement - ANTISENILIN
This excerpt taken from the ILNS 10-Q filed May 13, 2009.
GSK Option and License Agreement - ANTISENILIN. On April 29, 2009, we entered into an Option Agreement (the “Agreement”) with Glaxo Group Limited (“GSK”) regarding an option to purchase a license under certain of Intellect’s patents and patent applications (the “Subject Patents”) related to antibodies and methods of treatment for Alzheimer’s disease. ...
http://www.wikinvest.com/stock/Intellect_Neurosciences_(ILNS)/Gsk_Option_License_Agreement_Antisenilin
---------------------------------------------------------------
GSK clinicaltrials
Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
http://www.clinicaltrials.gov/ct2/show/NCT01342926?term=GSK933776&rank=4
.,
Did someone call or email to Mr. Shapiro / Mr. Maza about some questions of date change?
.,
No Supreme Court works in mid-August ... They are all on vacation!
It seems like a joke!
The cases are only 2:
a) Date will change again, probably it will be September ...
b) There will be an agreement between Pfizer and Intellect by August, 12 ...
.,
To Mr. Buckiii2
See post of Mr. Dealsintime12 :
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=104459090
.,
Only Mr. Deals or lawyer Shapiro can enlighten us!
All shareholders ILNS are tired of constant delays, it looks like the "soap opera Beautiful" that never ends ...
I admired the very fast acquisition of Shire on Viropharma and then the acquisition of AbbVie on Shire ...
We're waiting update more than 1 year from ILNS ...
SOON, as Mr. Maza says always since 2013!
.,
I don't understand why Shapiro has been waiting long months to see the clause(s) in contract ...
He told:
As a attorney, member of the bar, I knew there was a clause in the contract. I knew they had, they would have interest, ...
.,
ILNS's OX1 trial for Friedreich's ataxia will be carried out by AbbVie ...
http://www.reuters.com/article/2014/07/18/us-abbvie-shire-idUSKBN0FN0X620140718
.,
U.S. drugmaker AbbVie finally wins Dublin's Shire with $55 billion deal
LONDON Fri Jul 18, 2014 9:51am EDT
(Reuters) - U.S. drugmaker AbbVie (ABBV.N) bought Dublin-based Shire (SHP.L) on Friday in a 32 billion-pound ($54.7 billion) deal that will allow it to slash its tax bill by relocating to Britain.
The London-listed company, which makes expensive medicines to treat rare diseases, fought off four earlier bids from AbbVie until the U.S. firm raised its price to 52.48 pounds per share - made up of 24.44 pounds in cash and 0.8960 new AbbVie shares.
Chicago-based AbbVie is buying Shire to cut both its U.S. tax bill and its reliance on arthritis drug Humira, the world's top selling medicine which loses U.S. patent protection in 2016. AbbVie, which generates nearly 60 percent of its revenue from Humira, had until Friday to announce a firm offer for Shire, extend the deadline or walk away under UK takeover rules.
It now plans to create a combined company incorporated in Jersey, the Channel Islands, which will pay an effective tax of about 13 percent, sharply lower than its current rate of about 22 percent, making the deal one of the biggest driven by the tactic known as tax inversion.
America's Pfizer Inc tried a similar tactic earlier this year when it made a bid for Britain's AztraZeneca plc (AZN.L) though its $118 billion deal was rejected.
Shire's board had said on Monday it was ready to recommend the higher offer from AbbVie, signaling the end of a lengthy courtship.
AbbVie's agreed price represents a premium of about 53 percent to Shire's share price on May 2, the last business day before AbbVie's first offer, which was rebuffed by Shire.
Shares in Shire, which will own about 25 percent of the combined group, rose 1.9 percent to 48.99 pounds by 1027 GMT on Friday after the agreed deal was announced.
Separately, Shire raised its earnings guidance for the year on Friday, to low-to-mid 30 percent growth, from mid-to-high 20 percent growth. The company, which also produces hyperactivity drug Vyvanse, reported record revenue of $1.5 billion for its second quarter and a 42 percent jump in its preferred earnings measure of non-GAAP adjusted earnings per ADS to $2.67.
Commenting on the final takeover deal, AbbVie chairman and chief executive Richard Gonzalez said the combination would have a best-in-class product development platform, a stronger pipeline and better R&D capabilities.
"The combination of AbbVie and Shire is attractive for shareholders of both companies," he said.
Shire was advised by Goldman Sachs, Morgan Stanley, Deutsche Bank, Evercore and Citi, while AbbVie was advised by J.P.Morgan.
($1 = 0.5847 British Pounds)
(Editing by Sophie Walker)
http://www.reuters.com/article/2014/07/18/us-abbvie-shire-idUSKBN0FN0X620140718
----------------------------------------------------
Trial for Friedreich's ataxia (OX1 - owned by ILNS) from today will be carried out by AbbVie ...
.,
Shire Plc and U.S. drugmaker Abbvie Inc plan to announce a $53 billion merger as soon as Friday morning, two people said on Thursday.
Dublin-based Shire, which sells drugs for rare diseases, said earlier this week it was ready to recommend a deal to shareholders after AbbVie increased its offer.
AbbVie, which is based in Chicago and makes top-selling arthritis drug Humira, boosted its bid for Shire to 53.20 pounds per share on Sunday. Shire has rejected four previous bids.
The people cautioned the deal could still take longer to complete and the deadline for an offer could be extended.
Under British takeover rules AbbVie has until July 18 to announce a firm offer for Shire, extend the deadline for an offer, or walk away.
AbbVie is eager to buy Shire both to reduce its U.S. tax bill by moving its tax base to Britain - a tactic known as inversion - and to diversify its drug portfolio. AbbVie currently generates nearly 60 percent of its revenue from Humira, the world's top-selling medicine, which loses U.S. patent protection in late 2016.
AbbVie's move is the second attempt by a U.S. drugmaker to buy a London-listed rival after Pfizer Inc's $118 billion pursuit of AstraZeneca Plc failed in May over price.
Reuters reported on Saturday that Shire had asked AbbVie to sweeten its offer to near 53 pounds per share so it could recommend the deal. Shire confirmed the news on Monday.
http://www.reuters.com/article/2014/07/17/us-shire-abbvie-sale-idUSKBN0FM27220140717
.,
I think you're right, we need to know if the Official Action from the EPO has accepted the complaint of ILNS.
( ... which we anticipate will be scheduled for early next year )
NEXT YEAR is now 2014
-------------------------------------------------
I wrote in my previous post:
My intention was to report to the court Oing the conduct of Pfizer for trial Bapineuzumab ...
This is to confirm what Shapiro said about conduct of Pfizer for trial Ponezumab ...
---------------------------------------------
What do you think about?
We must inform Shapiro about that?
-------------------------------------------------
Intellect Neurosciences Issues Letter to Shareholders
NEW YORK, Feb. 13, 2013 (GLOBE NEWSWIRE) ..........................
ANTISENILIN patents:
For reasons that are unclear to us, Johnson & Johnson and Pfizer are continuing in their opposition to our ANTISENILIN patent in Europe, having responded quite aggressively to our appeal notice and submissions even after the Bapineuzumab Phase 3 results were announced. We are considering our response and strategy leading up to the Oral Hearings in Munich, which we anticipate will be scheduled for early next year. Meanwhile, we are waiting for an Official Action from the EPO with regard to our pending divisional patent application that aims to overcome the formalistic objections raised in the opposition. If the EOP grants us a patent on this second application, the opposition becomes moot.
We received a first official action from the USPTO to our continuation-in-part application in which we are seeking additional claims, including to the amino terminus of Aß. We believe the arguments from the Examiner are quite straightforward to address and we are preparing our response. If successful, the issuance of this second patent would trigger another $2 million milestone payment from certain of our global pharmaceutical licensees.
http://ir.stockpr.com/intellectns/press-releases/detail/893/intellect-neurosciences-issues-letter-to-shareholders
.,
My intention was to report to the court Oing the conduct of Pfizer for trial Bapineuzumab ...
This is to confirm what Shapiro said about conduct of Pfizer for trial Ponezumab ...
Thanks for the link ...
.,
Unfortunately, Mr. Maza does not answer, we must be certain that ILNS does not hold the patent for Europe.
We cannot report to Shapiro or to Oing an anomaly if we're not sure ...
Anyway thanks for the update!
.,
Is it important to report the following anomaly to the judge OING or to lawyer Shapiro?
Few years ago, Pfizer said that Bapineuzumab does not work ...
Nevertheless, Pfizer continues research in Europe by Wyeth Pharmaceuticals Inc. (Wholly owned subsidiary) ... Pfizer is behaving like Ponezumab, they say that does not work, however trials are ongoing ...
I don't know if the web pages has been updated!
------------------------------------------------------------------------
Trial status: ongoing for FRANCE, BELGIUM, SLOVAKIA
Trial protocol: FR (Ongoing) GB (Prematurely Ended) BE (Ongoing) ES (Prematurely Ended) PT (Prematurely Ended) SK (Ongoing) IT (Prematurely Ended) FI (Prematurely Ended) NL (Prematurely Ended) SE (Prematurely Ended) AT (Prematurely Ended) DE (Prematurely Ended)
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-015079-29
-----------------------------------------------------------------
National Competent Authority: FRANCE
Name of Sponsor: Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA
https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015079-29/FR#summary
-----------------------------------------------------------------
National Competent Authority: BELGIUM
Name of Sponsor: Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA
https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015079-29/BE
-----------------------------------------------------------------
National Competent Authority: SLOVAKIA
Name of Sponsor: Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA
https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015079-29/SK
-----------------------------------------------------------------
.,
I understand you, however if you believe in ILNS, it is better pay few dollars more and buy now.
The next week you may regret, because you will pay shares a lot more!
Instead, I do not understand who sells for ridiculous figures in this time, they will repent bitterly ...
.,
Is Bapineuzumab trial ongoing in Europe?
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-015079-29
.,
The seller of 20,000 shares with the gain by $ 0.0070 to $ 0.0079 = $ 20 - tax, this evening will be able to party with friends ... !
.,
No shareholder has wanted sell today or in the past months. All shareholders holding their shares jealously tight, waiting for the big day ...
As in all stock market, sometimes, someone sells a portion of shares for cash needs.
You probably follow by short time ILNS, I assure you that there is only one "manipulator" he buys or sells shares ILNS by years, for balance the value to $ 0.007 ...
Check the graphs of the past months, you will notice that on days with large volumes traded, the average price remains on the same level ...
Do not ask me why or which Pharma is behind the "manipulator", no one is able to understand!
.,